DE69739725D1 - Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) - Google Patents
Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28)Info
- Publication number
- DE69739725D1 DE69739725D1 DE69739725T DE69739725T DE69739725D1 DE 69739725 D1 DE69739725 D1 DE 69739725D1 DE 69739725 T DE69739725 T DE 69739725T DE 69739725 T DE69739725 T DE 69739725T DE 69739725 D1 DE69739725 D1 DE 69739725D1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- identification
- antigenes
- binding interactions
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74636196A | 1996-11-08 | 1996-11-08 | |
PCT/US1997/019906 WO1998019706A1 (en) | 1996-11-08 | 1997-10-29 | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69739725D1 true DE69739725D1 (de) | 2010-02-11 |
Family
ID=25000516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69739725T Expired - Lifetime DE69739725D1 (de) | 1996-11-08 | 1997-10-29 | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) |
Country Status (14)
Country | Link |
---|---|
EP (2) | EP1878748A2 (de) |
JP (3) | JP4048294B2 (de) |
KR (1) | KR100510604B1 (de) |
CN (1) | CN1198646C (de) |
AT (1) | ATE453406T1 (de) |
AU (1) | AU739058B2 (de) |
BR (1) | BR9713498A (de) |
CA (1) | CA2270922A1 (de) |
DE (1) | DE69739725D1 (de) |
HK (1) | HK1025741A1 (de) |
ID (1) | ID21676A (de) |
NO (1) | NO992212L (de) |
RU (1) | RU2221590C2 (de) |
WO (1) | WO1998019706A1 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
JP3521382B2 (ja) | 1997-02-27 | 2004-04-19 | 日本たばこ産業株式会社 | 細胞間接着及びシグナル伝達を媒介する細胞表面分子 |
US7112655B1 (en) | 1997-02-27 | 2006-09-26 | Japan Tobacco, Inc. | JTT-1 protein and methods of inhibiting lymphocyte activation |
CN1068524C (zh) * | 1997-06-23 | 2001-07-18 | 叶庆炜 | 一种治疗顽症牛皮癣的药物 |
US6972125B2 (en) | 1999-02-12 | 2005-12-06 | Genetics Institute, Llc | Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith |
JP2002540764A (ja) | 1999-02-12 | 2002-12-03 | ジェネティックス・インスチチュート・インコーポレーテッド | B7分子と反応するヒト化免疫グロブリンおよびそれを用いた治療方法 |
JP4210454B2 (ja) | 2001-03-27 | 2009-01-21 | 日本たばこ産業株式会社 | 炎症性腸疾患治療剤 |
JP3871503B2 (ja) | 1999-08-30 | 2007-01-24 | 日本たばこ産業株式会社 | 免疫性疾患治療剤 |
JP3597140B2 (ja) | 2000-05-18 | 2004-12-02 | 日本たばこ産業株式会社 | 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途 |
WO2001089567A1 (en) * | 2000-05-22 | 2001-11-29 | Idec Pharmaceuticals Corporation | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigens |
IL152886A0 (en) | 2000-06-06 | 2003-06-24 | Bristol Myers Squibb Co | B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
CN100574803C (zh) * | 2001-01-31 | 2009-12-30 | 拜奥根Idec公司 | 免疫调节抗体在治疗肿瘤性疾病中的用途 |
JP4212278B2 (ja) * | 2001-03-01 | 2009-01-21 | 日本たばこ産業株式会社 | 移植片拒絶反応抑制剤 |
WO2003039486A2 (en) * | 2001-11-09 | 2003-05-15 | Idec Pharmaceuticals Corporation | Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies |
US20040152105A1 (en) * | 2002-09-06 | 2004-08-05 | Cytos Biotechnology Ag. | Immune modulatory compounds and methods |
US20090053249A1 (en) * | 2004-07-20 | 2009-02-26 | Yan Qi | Specific Inhibition of Autoimmunity and Diseases Associated With Autoantigens |
CN1817909B (zh) * | 2005-02-08 | 2010-08-11 | 复旦大学 | 一种双功能融合蛋白 |
CN100369931C (zh) * | 2005-04-07 | 2008-02-20 | 苏州大学 | 抗人b7-1分子单克隆抗体及其应用 |
EP2161336B2 (de) * | 2005-05-09 | 2017-03-29 | ONO Pharmaceutical Co., Ltd. | Humane monoklonale Antikörper für den programmierten Tod 1 (PD-1) und Verfahren zur Behandlung von Krebs mit PD-1-Antikörpern allein oder in Kombination mit anderen Immunotherapeutika |
US7510844B2 (en) | 2006-01-24 | 2009-03-31 | Bristol-Myers Squibb Company | CD86 and CD80 receptor competition assays |
JP2013528360A (ja) | 2010-04-09 | 2013-07-11 | アムジェン インコーポレイテッド | Btnl9タンパク質、核酸および抗体ならびにそれらの使用 |
EP2804619B1 (de) * | 2012-01-16 | 2021-10-13 | Atox Bio Ltd. | Reltecimod zur behandlung von bakteriellen infektionen |
CZ306905B6 (cs) | 2013-06-11 | 2017-09-06 | Česká zemědělská univerzita v Praze | Způsob pro stanovení vodní hodnoty sněhu sněhové vrstvy a zařízení pro provádění tohoto způsobu |
CN106177931B (zh) * | 2016-08-25 | 2018-02-02 | 河北浓孚雨生物科技有限公司 | 免疫检测点双阻断ctl高效率杀伤细胞制剂的制备方法 |
TW202034951A (zh) | 2018-12-07 | 2020-10-01 | 日商小野藥品工業股份有限公司 | 免疫抑制劑 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6641809B1 (en) * | 1990-03-26 | 2003-11-04 | Bristol-Myers Squibb Company | Method of regulating cellular processes mediated by B7 and CD28 |
DE122007000078I2 (de) * | 1991-06-27 | 2011-01-13 | Bristol Myers Squibb Co | CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung |
US6113898A (en) * | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
-
1997
- 1997-10-29 CN CNB971812896A patent/CN1198646C/zh not_active Expired - Fee Related
- 1997-10-29 CA CA002270922A patent/CA2270922A1/en not_active Abandoned
- 1997-10-29 ID IDW990357D patent/ID21676A/id unknown
- 1997-10-29 DE DE69739725T patent/DE69739725D1/de not_active Expired - Lifetime
- 1997-10-29 AT AT97913955T patent/ATE453406T1/de not_active IP Right Cessation
- 1997-10-29 JP JP52163398A patent/JP4048294B2/ja not_active Expired - Fee Related
- 1997-10-29 EP EP07013357A patent/EP1878748A2/de not_active Withdrawn
- 1997-10-29 EP EP97913955A patent/EP1007090B1/de not_active Expired - Lifetime
- 1997-10-29 AU AU51009/98A patent/AU739058B2/en not_active Ceased
- 1997-10-29 WO PCT/US1997/019906 patent/WO1998019706A1/en active IP Right Grant
- 1997-10-29 RU RU99112112/15A patent/RU2221590C2/ru not_active IP Right Cessation
- 1997-10-29 BR BR9713498-8A patent/BR9713498A/pt not_active Application Discontinuation
- 1997-10-29 KR KR10-1999-7004067A patent/KR100510604B1/ko not_active IP Right Cessation
-
1999
- 1999-05-06 NO NO19992212A patent/NO992212L/no not_active Application Discontinuation
-
2000
- 2000-08-09 HK HK00104965A patent/HK1025741A1/xx not_active IP Right Cessation
-
2007
- 2007-07-17 JP JP2007185903A patent/JP4320381B2/ja not_active Expired - Fee Related
-
2008
- 2008-06-18 JP JP2008158896A patent/JP2009001570A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR9713498A (pt) | 2000-02-29 |
NO992212L (no) | 1999-07-08 |
EP1878748A2 (de) | 2008-01-16 |
CN1198646C (zh) | 2005-04-27 |
JP2007330261A (ja) | 2007-12-27 |
JP4048294B2 (ja) | 2008-02-20 |
WO1998019706A1 (en) | 1998-05-14 |
CN1244128A (zh) | 2000-02-09 |
AU739058B2 (en) | 2001-10-04 |
HK1025741A1 (en) | 2000-11-24 |
JP4320381B2 (ja) | 2009-08-26 |
NO992212D0 (no) | 1999-05-06 |
RU2221590C2 (ru) | 2004-01-20 |
JP2009001570A (ja) | 2009-01-08 |
AU5100998A (en) | 1998-05-29 |
KR100510604B1 (ko) | 2005-08-31 |
JP2001504693A (ja) | 2001-04-10 |
ATE453406T1 (de) | 2010-01-15 |
EP1007090A4 (de) | 2001-03-14 |
CA2270922A1 (en) | 1998-05-14 |
EP1007090B1 (de) | 2009-12-30 |
EP1007090A1 (de) | 2000-06-14 |
ID21676A (id) | 1999-07-08 |
KR20000053137A (ko) | 2000-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69739725D1 (de) | Identifikation von bindungs- interaktionen zwischen gewissen antikorpern und den humanen costimulatorischen antigenen b7.1 (cd80) und b7.2 (cd28) | |
PT892643E (pt) | Metodos para inibir uma resposta imunitaria bloqueando os circuitos de gp39/cd40 e ctla4/cd28/b7 e composicoes utilizaveis para o efeito | |
MXPA02001911A (es) | Anticuerpos ctla-4 humanos y sus usos. | |
DK0955995T3 (da) | Anvendelse af komplekser til fremstilling af præparater til behandling af sensibel hud, fremgangsmåde til fremstilling af hypoallergene præparater | |
NL300220I1 (nl) | Immunoglobuline varianten voor specifieke FC-epsilon receptoren. | |
HK1083510A1 (en) | Antibodies against pd-1 and uses thereof | |
DK83092D0 (da) | Fremgangsmaade til udvinding af thrombin | |
ATE202706T1 (de) | Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom | |
EP1194164A4 (de) | Prion protein peptide und deren verwendung | |
MXPA02012157A (es) | Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos. | |
CA2218289A1 (en) | Cd45rb binding compounds for the prevention of transplant rejection | |
HK1025738A1 (en) | Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation | |
DE69510779T2 (de) | Nematizide proteine | |
DE68918391D1 (de) | Okulare hypotensive Mittel. | |
HK1025500A1 (en) | Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases | |
EP1401496A4 (de) | Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge | |
OA09384A (fr) | "Système matriciel autoadhésif pour la libération prolongée du piribédil par voie transcutanée". | |
DE59008012D1 (de) | Mittel zur Behandlung von Leder und Pelzen. | |
WO2000055194A3 (en) | Tuberculosis antigens and methods of use therefor | |
ATE133103T1 (de) | Verwendung von aminoalkanolamidestern als verarbeitungshilfsmittel für thermoplastische kunststoffe | |
DE69810724D1 (de) | Verwendung von Protein C Inhibitor zur Behandlung disseminierter intravasaler Gerinnung (DIC) | |
Friccius et al. | Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the co-receptor CD28 and its ligand B7 | |
EP0651800A4 (de) | Proteine aus granulabasophilen zellen. | |
FR2670079B1 (fr) | Dispositif pour la pre-taille des sarments sur les pieds de vigne dans des plantations avec palissage. | |
DK0854727T3 (da) | Tumorafstødelsesantigener, der præsenteres af HLA-B44-molekyler, og anvendelser af samme |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |